Answers are grounded in this paper and cite their sources.
The management of recurrent or metastatic vulvar squamous cell carcinoma (VSCC) remains challenging due to the absence of standardized systemic therapies. While immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are promising, their efficacy is traditionally linked to biomarkers such as PD-L1 expression or microsatellite instability-high (MSI-H) status. Here, we report an atypical case of a 23-year-old patient with advanced PD-L1-negative (CPS <1) and microsatellite stable (MSS) VSCC who achieved sustained partial remission following treatment with sintilimab (anti-PD-1), bevacizumab, and chemotherapy. Initially resistant to platinum-based chemotherapy, the patient exhibited rapid symptomatic relief and imaging-confirmed tumor reduction after two cycles of combination therapy, with durable response maintained through six cycles. This case challenges conventional biomarker paradigms, suggesting that ICIs combined with anti-angiogenic and cytotoxic agents may overcome resistance in PD-L1/MSS VSCC. In addition, we provide a comprehensive review of the current literature that the synergistic interplay between immune modulation, vascular normalization, and chemotherapy likely contributed to this outcome, underscoring the need for broader predictive frameworks beyond PD-L1 and MSI-H to optimize immunotherapy selection in rare gynecologic malignancies.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: